Stock Evaluator: Cytek Biosciences, Inc. (CTKB)

Cytek Biosciences, Inc. CTKB

$4.19 -0.13 -2.90%
July 31, 2026 12:30:03 PM EST November 10, 2021 Volume: 211,273
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Life Sciences Tools & Services

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Commentary & Analysis


Financial Summary

Share Statistics CTKB Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $556.6 $1,774.7 39%
Shares Out (Mil) 128.7 94.8 68%
Institutional Ownership 83.7% 90.1% 52%
Float (Mil) 96.6 69.9 61%
Beta 1.17 1.20 69%
Avg Daily Volume (000s) 648 838 63%
Price Change
(52-week)
19.7% 81.0% 62%
Growth CTKB Industry
Median
Percentile
(All Stocks)
Sales (5yr) 16.8% 7.8% 77%
Net Income (5yr) (40.3%) (13.7%) 9%
EPS (5yr) (48.5%) 0.7% 4
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (15.0%) (15.0%) 52%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 1 1 1
Current EPS ($0.020) ($0.030) $0.200
Month Ago EPS ($0.010) ($0.040) $0.190
# Rev Up 0 0 0
# Rev Down 1 1 1
Three Months Ago EPS ($0.050) ($0.130) $0.060
Year/Year Chg (86.7%) (94.2%) (155.7%)
Financials CTKB Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $204 $763 32%
Net Income (TTM) (Mil) ($74) ($14) 13%
EPS (TTM) ($0.579) ($0.200) 26%
Operating Cash Flow (TTM) (Mil) ($7) $53 22%
Net Cash Flow (TTM) (Mil) ($30) ($5) 23%
Long-Term Debt (Q1) (Mil) $14 $270 30%
Enterprise Value (Q1) (Mil) $354 $2,430 31%
Valuation CTKB Industry
Median
Percentile
(All Stocks)
P/B 1.70 3.00 45%
P/E na 43.5 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 5.3 na
Ratios CTKB Industry
Median
Percentile
(All Stocks)
Gross Margin 51.7% 47.6% 64%
Net Margin (36.2%) (2.9%) 14%
ROA (15.9%) (3.2%) 22%
ROE (20.9%) (4.5%) 23%
Liabilities to Assets 27.0% 43.0% 18%
F-Score 2 5 7%

Passing Stock Screens

As of 7/30/2026, from a list of 60 stock screening strategies, CTKB meetings the criteria of 1 screen:

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors